Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

Literature DB >> 22203585

Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

Johanne Blais¹, Stacey R Lewis, Kevin M Krause, Bret M Benton.

Abstract

TD-1792 is a new multivalent glycopeptide-cephalosporin antibiotic with potent activity against Gram-positive bacteria. The in vitro activity of TD-1792 was tested against 527 Staphylococcus aureus isolates, including multidrug-resistant isolates. TD-1792 was highly active against methicillin-susceptible S. aureus (MIC(90), 0.015 μg/ml), methicillin-resistant S. aureus, and heterogeneous vancomycin-intermediate S. aureus (MIC(90), 0.03 μg/ml). Time-kill studies demonstrated the potent bactericidal activity of TD-1792 at concentrations of ≤ 0.12 μg/ml. A postantibiotic effect of >2 h was observed after exposure to TD-1792.

Entities: Chemical Species

Mesh：

Substances：

Year: 2011 PMID： 22203585 PMCID： PMC3294951 DOI： 10.1128/AAC.05532-11

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

8 in total

Review 1. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors: Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal: Clin Infect Dis Date: 2009-01-01 Impact factor: 9.079

2. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

Authors: Daniel D Long; James B Aggen; Jason Chinn; Seok-Ki Choi; Burton G Christensen; Paul R Fatheree; David Green; Sharath S Hegde; J Kevin Judice; Koné Kaniga; Kevin M Krause; Michael Leadbetter; Martin S Linsell; Daniel G Marquess; Edmund J Moran; Matthew B Nodwell; John L Pace; Sean G Trapp; S Derek Turner
Journal: J Antibiot (Tokyo) Date: 2008-10 Impact factor: 2.649

3. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles.

Authors: D S Kernodle; C W Stratton; L W McMurray; J R Chipley; P A McGraw
Journal: J Infect Dis Date: 1989-01 Impact factor: 5.226

4. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Authors: Kimberly D Leuthner; Celine Vidaillac; Chrissy M Cheung; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191

5. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Authors: Sharath S Hegde; Olanrewaju O Okusanya; Robert Skinner; Jeng-Pyng Shaw; Glenmar Obedencio; Paul G Ambrose; Johanne Blais; Sujata M Bhavnani
Journal: Antimicrob Agents Chemother Date: 2011-12-12 Impact factor: 5.191

Review 6. Antibiotics for emerging pathogens.

Authors: Michael A Fischbach; Christopher T Walsh
Journal: Science Date: 2009-08-28 Impact factor: 47.728

7. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants.

Authors: D S Kernodle; P A McGraw; C W Stratton; A B Kaiser
Journal: Antimicrob Agents Chemother Date: 1990-03 Impact factor: 5.191

8. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.

Authors: In-Gyu Bae; Giang T Tonthat; Martin E Stryjewski; Thomas H Rude; Lindsay F Reilly; Steven L Barriere; Fredric C Genter; G Ralph Corey; Vance G Fowler
Journal: J Clin Microbiol Date: 2009-10-21 Impact factor: 5.948

8 in total

12 in total

1. In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Authors: Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Ellie J C Goldstein
Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191

Review 2. Antibiotics in the clinical pipeline at the end of 2015.

Authors: Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal: J Antibiot (Tokyo) Date: 2016-06-29 Impact factor: 2.649

Review 3. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors: Karen Bush; Malcolm G P Page
Journal: J Pharmacokinet Pharmacodyn Date: 2017-02-04 Impact factor: 2.745

Review 9. β-Lactam Antibiotics Renaissance.

Authors: Wenling Qin; Mauro Panunzio; Stefano Biondi
Journal: Antibiotics (Basel) Date: 2014-05-09

Review 10. Multitarget Approaches against Multiresistant Superbugs.

Authors: Declan Alan Gray; Michaela Wenzel
Journal: ACS Infect Dis Date: 2020-03-19 Impact factor: 5.084